Aeglea Biotherapeutics

Receive alerts
Market Cap:
$227.25 m
7.84 USD
52 weeks high
52 weeks low

In brief

Discovery and Innovation

As a leader in creating and developing novel engineered human enzymes to degrade specific amino acids in the blood, we are focused on providing safe and effective products to patients.

What does success mean to us? It means…

. Unlocking the potential therapeutic value of engineered human enzymes while avoiding immune responses
. Meeting serious unmet medical needs in rare genetic diseases, inborn errors of metabolism, and cancers with ground-breaking treatments
. Transforming lives, especially those of children and families

Built on discovery, technology, and opportunity, our biotechnology company was founded in 2013 to develop and bring to market the engineered human enzymes invented in the lab of Professor George Georgiou, Ph.D., University of Texas at Austin.